DE60237645D1 - Immunstimulierendes Mittel enthaltend eine Biomasse von methanotrophem Bakterium - Google Patents

Immunstimulierendes Mittel enthaltend eine Biomasse von methanotrophem Bakterium

Info

Publication number
DE60237645D1
DE60237645D1 DE60237645T DE60237645T DE60237645D1 DE 60237645 D1 DE60237645 D1 DE 60237645D1 DE 60237645 T DE60237645 T DE 60237645T DE 60237645 T DE60237645 T DE 60237645T DE 60237645 D1 DE60237645 D1 DE 60237645D1
Authority
DE
Germany
Prior art keywords
biomass
strain
agent containing
immunostimulating agent
methanotrophic bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60237645T
Other languages
English (en)
Inventor
Lars Jorgensen
Arild Johannessen
Karen Moller Jensen
Gunnar Kleppe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Equinor ASA
Original Assignee
Statoil ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statoil ASA filed Critical Statoil ASA
Application granted granted Critical
Publication of DE60237645D1 publication Critical patent/DE60237645D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Birds (AREA)
  • Animal Husbandry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Insects & Arthropods (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Sustainable Development (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
DE60237645T 2002-02-28 2002-05-31 Immunstimulierendes Mittel enthaltend eine Biomasse von methanotrophem Bakterium Expired - Lifetime DE60237645D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0204722.3A GB0204722D0 (en) 2002-02-28 2002-02-28 Method
PCT/GB2002/002555 WO2003072133A2 (en) 2002-02-28 2002-05-31 Immunostimulatory agent comprising a biomass of methanotrophic bacterium

Publications (1)

Publication Number Publication Date
DE60237645D1 true DE60237645D1 (de) 2010-10-21

Family

ID=9931987

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60237645T Expired - Lifetime DE60237645D1 (de) 2002-02-28 2002-05-31 Immunstimulierendes Mittel enthaltend eine Biomasse von methanotrophem Bakterium

Country Status (10)

Country Link
US (1) US20050163802A1 (de)
EP (1) EP1478376B1 (de)
CN (1) CN1622815B (de)
AT (1) ATE480247T1 (de)
AU (1) AU2002257966A1 (de)
CA (1) CA2477371C (de)
DE (1) DE60237645D1 (de)
GB (1) GB0204722D0 (de)
NO (1) NO332176B1 (de)
WO (1) WO2003072133A2 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
CN100548411C (zh) 2003-03-31 2009-10-14 精达制药公司 设置有内部压力释放部件的渗透泵
GB0315783D0 (en) 2003-07-04 2003-08-13 Norferm Da Use
NO323529B1 (no) * 2004-05-13 2007-06-04 Trouw Internat Bv Framgangsmate for reduksjon av innholdet av uonskede naeringsstoffer i avlopsvann fra fiskeoppdrettsanlegg.
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
CN101951786A (zh) * 2007-12-21 2011-01-19 希尔氏宠物营养品公司 宠物食品组合物
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
NO333891B1 (no) * 2009-01-28 2013-10-14 Trouw Internat Bv Fiskefôr med forhøyet innhold av arginin og framgangsmåte for å forhindre redusert tilvekst for anadrom fisk ved utsett til sjø ved å anvende et slikt fôr
WO2010128312A2 (en) * 2009-05-08 2010-11-11 Bioprotein As Feed composition for the treatment or prevention of enteritis in fish
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
KR20150036502A (ko) 2012-07-13 2015-04-07 칼리스타, 인코포레이티드 바이오리파이너리 시스템, 이의 방법 및 조성물
DK2917358T3 (da) 2012-11-09 2019-09-30 Calysta Inc Sammensætninger og fremgangsmåder til biologisk fremstilling af fedtsyrederivater
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
WO2018204792A2 (en) * 2017-05-05 2018-11-08 White Dog Labs, Inc. Single cell protein products and an integrated method for the production of ethanol and single cell protein
US10883123B2 (en) 2017-06-09 2021-01-05 White Dog Labs, Inc. Integrated wet-mill method for the production of ethanol and single cell protein
GB201712459D0 (en) 2017-08-02 2017-09-13 Norges Miljø-Og Biovitenskapelige Univ Treatment or prevention of gastrointestinal dysbiosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314820A (en) * 1987-11-13 1994-05-24 Kuwait Institute For Scientific Research Process and microorganisms for producing single cell protein
EP0640348A1 (de) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Adjuvansmischung auf Ölbasis und auf Wasserbasis
GB0003620D0 (en) * 2000-02-16 2000-04-05 Norferm Da Method
GB0120047D0 (en) * 2001-08-16 2001-10-10 Norferm Da Product

Also Published As

Publication number Publication date
CN1622815A (zh) 2005-06-01
CA2477371C (en) 2012-07-10
EP1478376B1 (de) 2010-09-08
CA2477371A1 (en) 2003-09-04
CN1622815B (zh) 2012-08-22
WO2003072133A2 (en) 2003-09-04
ATE480247T1 (de) 2010-09-15
EP1478376A2 (de) 2004-11-24
NO20043741L (no) 2004-09-07
AU2002257966A1 (en) 2003-09-09
US20050163802A1 (en) 2005-07-28
WO2003072133A3 (en) 2003-11-20
AU2002257966A8 (en) 2003-09-09
NO332176B1 (no) 2012-07-16
GB0204722D0 (en) 2002-04-17

Similar Documents

Publication Publication Date Title
DE60237645D1 (de) Immunstimulierendes Mittel enthaltend eine Biomasse von methanotrophem Bakterium
ATE302265T1 (de) Einen lactobacillus-stamm enthaltende zusammensetzung und verwendungen davon
PE20010829A1 (es) Alimento para mascotas destinado al tratamiento de la especie helicobacter en las mascotas
BRPI0417826A (pt) bifidobactéria pseudolongum probiótica canina
SE0402406D0 (sv) Probiotic lactobacillus strains for improved vaginal health
DE60316772D1 (de) Von menschen oder tieren verwenbare diätetische und/oder pharmazeutische zubereitungen, auf basis von probiotischen mikroorganismen
Zhang et al. The severity of motile Aeromonas septicemia caused by virulent Aeromonas hydrophila in channel catfish is influenced by nutrients and microbes in water
BRPI1006135A2 (pt) Bactérias do ácido láctico e seu uso em produtos microbianos para ração direta a suínos
DK1624762T3 (da) Probiotisk præparat med mindst to mælkesyrebakteriestammer som er i stand til kolonisere mavetarmkanalen, i kombination med at de besidder overlevelsesegenskab, tarmbindende egenskab, en infektionsbeskyttelsesegenskab og en fiberfermenterende egenskab
Wang et al. Probiotic and safety properties screening of Enterococcus faecalis from healthy Chinese infants
Rumbaugh et al. Pseudomonas aeruginosa strains obtained from patients with tracheal, urinary tract and wound infection: variations in virulence factors and virulence genes
HK1078902A1 (en) Pathogenicity determinants which can be used as targets for developing means for preventing and controlling bacterial infections and/or systemic dissemination
Zhou et al. Probiotic potential analysis and safety evaluation of Enterococcus durans A8-1 isolated from a healthy Chinese infant
BR0309347A (pt) Uso de uma composição nutriente estéril, método de cultura de microorganismos, e, substrato de crescimento de microorganismo
US20140234259A1 (en) Natural Intra-Vaginal Inserts to Control Imbalanced pH
Prol‐García et al. Phaeobacter grown in biofilters: A new strategy for the control of Vibrionaceae in aquaculture
Laomongkholchaisri et al. Impact of potential probiotic Lactobacillus strains on host growth and development in a Drosophila melanogaster model
ATE466023T1 (de) Mannose-spezifische adhesinen und deren vervendung
ATE423196T1 (de) Antibiotikasensitive milchsäurebakterienstämme
ITMI20041232A1 (it) Composizione nutraceutica contenente un numero elevato di fermenti lattici utile come sinbiotico
Mishra et al. Isolation and characterization of probiotic microorganism from fermented dairy products
Rivis et al. Antagonistic activity of Bacillus probiotics against bacteria isolates of oral cavity of patients with periodontitis
RU2003112420A (ru) Биопрепарат лечебно-профилактического действия при эндометритах животных
Kolpen et al. WS02. 6 Increased bactericidal activity of colistin on Pseudomonas aeruginosa biofilms in anaerobic conditions
Pritchard et al. WS02. 8 Altered therapeutic susceptibility of mucoid Pseudomonas aeruginosa in artificial sputum medium